Anna Bohdanowicz-Pawlak
University of Wrocław
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anna Bohdanowicz-Pawlak.
Gynecological Endocrinology | 2004
Bednarek-Tupikowska G; Krzysztof Tupikowski; B. Bidzińska; Anna Bohdanowicz-Pawlak; J. Antonowicz-Juchniewicz; B. Kosowska; Andrzej Milewicz
Estradiol (E2) has antioxidant properties. The role of progestins in antioxidant defense is still unknown. We have evaluated the influence of E2 and E2 plus medroxyprogesterone acetate (MPA) on serum lipid peroxide (LPO) levels, a marker of free radical reactions, and serum total antioxidant status (TAS) in postmenopausal women. Subjects consisted of 26 women with surgical menopause, before and after 4 months of estrogen replacement therapy (ERT; E2), and 54 women with natural menopause on hormone replacement therapy (HRT; E2 plus MPA). Forty premenopausal women served as a control group. Serum E2 was estimated by radioimmunoassay, follicle-stimulating hormone by IRMA methods, LPO and TAS by colorimetric methods. Before therapy, LPO levels in the postmenopausal women were significantly higher (p < 0.001) than in the control group. After both ERT and HRT, LPO decreased significantly and did not differ between both groups and the control group. TAS was significantly lower in postmenopausal women (p < 0.001) than in the control group before therapy. After both ERT and HRT, TAS increased significantly and did not differ between both groups and the control group. We conclude that oxidative stress is increased after menopause. ERT and HRT inhibit the generation of free radicals and raise antioxidant potential to the levels found in premenopausal women. MPA did not influence the antioxidant action of E2.
Gynecological Endocrinology | 2008
Joanna Jakubowska; Anna Bohdanowicz-Pawlak; Andrzej Milewicz; Jadwiga Szymczak; Bednarek-Tupikowska G; Marek Demissie
Objectives. Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS). The aims of the present study were to establish other CVRF, such as plasma adiponectin, tumor necrosis factor-α (TNFα), interleukin-6 (IL-6) and C-reactive protein (CRP) levels, in obese premenopausal women with PCOS and to investigate the effect of metformin treatment on these factors. Materials and methods. The study group consisted of 29 PCOS woman with body mass index (BMI) >25 kg/m2. They were treated over 6 months with 500 mg metformin twice daily. Twenty-nine healthy individuals matched for age and BMI were controls. Adiponectin, TNFα, IL-6 and CRP levels were examined in all PCOS (before and after treatment) and control women. Results. In the PCOS group significantly lower plasma adiponectin and TNFα levels were observed, whereas there were no differences in plasma IL-6 and CRP levels between PCOS and control groups. Plasma adiponectin increased significantly after metformin treatment, but levels of inflammatory factors did not change.
Thyroid Research | 2013
Andrzej Lewiński; Anna Brona; Krzysztof Lewandowski; Diana Jędrzejuk; Anna Bohdanowicz-Pawlak; Elzbieta Skowronska-Jozwiak; Małgorzata Bieńkiewicz; Andrzej Milewicz
BackgroundIn order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor – TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor – TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1).Design and patientsThe study involved 23 patients treated with radioiodine for thyrotoxicosis. Serum concentrations of TSH, free T4, free T3, MMP-2, MMP-9, TIMP-1, TIMP-2, total adiponectin and TSP-1 were measured by immunoassays just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), 6 to 8 months (visit 4) and 15–18 months after radioiodine administration (visit 5).ResultsThere were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and TSP-1 (visit 1 vs. 2). Subsequently, there was an increase in MMP-2 (from 393±106 ng/ml to 774±424 ng/ml), TIMP-1 (from 177±76 ng/ml to 296±118 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518±9840 ng/ml), visit 1 to 5, respectively (p < 0.01). Further analysis revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p < 0.05), suggestive of possible decrease in free MMP-9 concentrations.ConclusionsOur data reveal a significant and sustained increase in serum adiponectin, as well as possible decrease of free MMP-9 concentration after radioiodine administration. In contrast, there was no significant change of TSP-1. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of subsequent cardiovascular and neoplastic disease.
Thyroid Research | 2013
Anna Brona; Anna Bohdanowicz-Pawlak; Joanna Jakubowska; Diana Jędrzejuk; Andrzej Milewicz
We have evaluated how levels of predictors of the cardiovascular risk such as: glucose, insulin, total cholesterol, high-density cholesterol, low-density cholesterol and triglycerides as well as adiponectin, fibrinogen, D-Dimers and CRP changed 24-28 weeks after treatment of hyperthyroidism in women with low and high titer of antibodies, and if their levels were different in these groups before and after treatment of hyperthyroidism. We compared also fT4 level before and after treatment in study groups. We investigated 35 postmenopausal women (non-smoking, aged 51-69 years) with subclinical and overt hyperthyroidism. We divided them into two groups according to titer of thyroid peroxidase antibodies: with low titer of antibodies (27 women) and high titer of antibodies (8 women). Statistical analysis revealed no difference in lipids profile, coagulation-fibrinolytic system, glucose, insulin, CRP and adiponectin level (before and after treatment) between groups with low and high titer of antibodies. No difference in fT4 level before and after treatment was found. In women with low titer of antibodies significant decrease was observed only in fT4 level (20.38 vs. 13.23 ng/ml). Levels of other factors did not differ before and after treatment. Triglycerides level decreased (133.00 vs. 89.13 mg/dl) and CRP level increased (2.95 vs. 4.48 mg/l) significantly after treatment in women with high titer of antibodies. Data suggest that it is more difficult to become euthyroid for women with hyperthyroidism and high titer of antibodies (there is no significant difference between fT4 level before and after treatment). Changes in metabolic profile and increase in inflammatory process are observed in women with hyperthyroidism and high titer of antibodies.
Gynecological Endocrinology | 1999
Bednarek-Tupikowska G; J. Kuryszko; B. Kosowska; Anna Bohdanowicz-Pawlak; Andrzej Milewicz
The influence of dehydroepiandrosterone (DHEA) in fodder on the histology of selected organs in rabbits with induced hypercholesterolemia and in healthy rabbits was studied. Rabbits were randomly assigned into four groups: (1) control; (2) atherogenic diet; (3) atherogenic diet with addition of DHEA; (4) normal diet with addition of DHEA. After 12 weeks, the rabbits were bled. Tissue samples were collected, fixed in a 0.4% solution of buffered formalin, dehydrated and embedded in paraffin. Fragments of 5-7 microns were stained with hematoxylin and eosin as well as according to the van Gieson method. Histological analysis showed features of steatosis and intense degenerative changes in analyzed organs of animals from group 2, i.e. liver, kidneys, adrenal glands, lungs and bone. The degenerative changes in the group which in addition to a fat-rich diet received DHEA, were similar to group 2, but much less intense. Histological pictures of organs of the rabbits which received DHEA and normal diet did not differ significantly from the control group. In animals with experimental hyperlipidemia, DHEA acts protectively, decreasing degenerative changes in internal organs caused by an atherogenic diet. DHEA does not change the histological picture of organs in healthy animals.
Medical Science Monitor | 2000
Bednarek-Tupikowska G; Gosk I; Szuba A; Anna Bohdanowicz-Pawlak; Kosowska B; Bożena Bidzińska; Andrzej Milewicz
Endokrynologia Polska | 2013
Anna Bohdanowicz-Pawlak; Jadwiga Szymczak; Ewa Waszczuk; Marek Bolanowski; Grażyna Bednarek-Tupikowska
Medical Science Monitor | 2008
Bednarek-Tupikowska G; Urszula Tworowska-Bardzińska; Krzysztof Tupikowski; Anna Bohdanowicz-Pawlak; Jadwiga Szymczak; Eliza Kubicka; Anna Skoczyńska; Andrzej Milewicz
Endokrynologia Polska | 1993
Marek Bolanowski; Andrzej Milewicz; Anna Bohdanowicz-Pawlak; Bednarek-Tupikowska G; Jedrzejak Ja; Lancranjan I
Endokrynologia Polska | 1993
Bednarek-Tupikowska G; Anna Bohdanowicz-Pawlak; Marek Bolanowski; Jedrzejak Ja; Andrzej Milewicz